ChiCTR2100048844 版本V1.1 版本创建时间2022/02/28 16:37:49 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100048844 

最近更新日期:

Date of Last Refreshed on:

2022-02-28 16:35:07 

注册时间:

Date of Registration:

2021-07-18 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

请与我们联系上传伦理批件。 液相色谱-串联质谱法分析长期佩戴角膜塑形镜后泪液中内源性小分子代谢物的变化

Public title:

The changes of endogenous small molecule metabolites in tears after wearing orthokeratology lens for a long time were analyzed by liquid chromatography-tandem mass spectrometry

注册题目简写:

English Acronym:

研究课题的正式科学名称:

液相色谱-串联质谱法分析长期佩戴角膜塑形镜后泪液中内源性小分子代谢物的变化

Scientific title:

The changes of endogenous small molecule metabolites in tears after wearing orthokeratology lens for a long time were analyzed by liquid chromatography-tandem mass spectrometry

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘国英 

研究负责人:

杜显丽 

Applicant:

Liu Guoying 

Study leader:

Du Xianli 

申请注册联系人电话:

Applicant telephone:

+86 18227321077

研究负责人电话:

Study leader's
telephone:

+86 15192552255

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1098063552@qq.com

研究负责人电子邮件:

Study leader's E-mail:

lilibestever@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省青岛市市南区燕儿岛路5号

研究负责人通讯地址:

山东省青岛市市南区燕儿岛路5号

Applicant address:

5 Yanerdao Road, Shinan District, Qingdao, Shandong, China

Study leader's address:

5 Yanerdao Road, Shinan District, Qingdao, Shandong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东省眼科研究所

Applicant's institution:

Shandong Eye Institute

研究负责人所在单位:

山东省眼科研究所

Affiliation of the Leader:

Shandong Eye Institute

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

青眼伦审(快)[2021]12号

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

青岛眼科医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Qingdao Eye Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

刘国英

Contact Name of the ethic committee:

Liu Guoying

伦理委员会联系地址:

青岛眼科医院

Contact Address of the ethic committee:

Qingdao Eye Hospital

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

青岛眼科医院

Primary sponsor:

Qingdao Eye Hospital

研究实施负责(组长)单位地址:

山东省青岛市市南区燕儿岛路5号

Primary sponsor's address:

5 Yanerdao Road, Shinan District, Qingdao, Shandong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

青岛

Country:

China

Province:

Shandong

City:

Qingdao

单位(医院):

青岛眼科医院

具体地址:

市南区燕儿岛路5号

Institution
hospital:

Qingdao Eye Hospital

Address:

5 Yanerdao Road, Shinan District

经费或物资来源:

肥大细胞在糖尿病角膜损伤修复中的作用及机制研究

Source(s) of funding:

Study on the role and mechanism of mast cells in the repair of diabetic corneal injury

研究疾病:

眼科疾病  

Target disease:

eye disease

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

1.调查佩戴角膜塑形镜2年后泪液中内源性小分子代谢物的变化; 2.以泪液中内源性小分子代谢物的变化为纽带,讨论长期佩戴角膜塑形镜与眼部组织潜在的生理或病理改变的关系。  

Objectives of Study:

1. To investigate the changes of endogenous small molecule metabolites in tears after wearing orthokeratology lens for 2 years; 2. The relationship between long-term wear of orthokeratology lens and potential physiological or pathological changes of eye tissue was discussed with the changes of endogenous small molecule.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.长期戴角膜塑形镜。

Inclusion criteria

1. Wearing orthokeratology lens for a long term.

排除标准:

1.有其他与角膜塑形镜无关眼科疾病。

Exclusion criteria:

1. Having other eye disease unreleate to orthokeratology lens.

研究实施时间:

Study execute time:

From 2021-07-16 00:00:00 To 2021-07-16 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-09-02 00:00:00 To 2021-09-02 00:00:00

干预措施:

Interventions:

组别:

病例组

样本量:

30

Group:

case group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

对照组

样本量:

30

Group:

control group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

青岛 

Country:

China

Province:

Shandong

City:

Qingdao

单位(医院):

青岛眼科医院 

单位级别:

三甲 

Institution
hospital:

Qingdao Eye Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

小分子代谢物

指标类型:

主要指标

Outcome:

Small molecule metabolites

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

泪液

组织:

Sample Name:

tear

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 8 years
最大 Max age 18 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

在临床医生上随机选择符合入选条件的人

Randomization Procedure (please state who generates the random number sequence and by what method):

The clinicians randomly selected those eligible for inclusion

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

向研究者联系索取 实验结束后6个月内

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

obtain from researcher

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据录入CRF 由研究者及负责人共同管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

data record on CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-07-18 09:24:09